Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 5, Mai 2015
Page(s) 499 - 505
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153105011
Publié en ligne 9 juin 2015
  1. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994 ; 76 : 597–598. [CrossRef]
  2. Leffler H, Carlsson S, Hedlund M, et al. Introduction to galectins. Glycoconj J 2004 ; 19 : 433–440. [CrossRef]
  3. Cooper DNW. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002 ; 1572 : 209–231. [CrossRef] [PubMed]
  4. Houzelstein D, Gonçalves IR, Orth A, et al. Lgals6, a 2-million-year-old gene in mice: a case of positive Darwinian selection and presence/absence polymorphism. Genetics 2008 ; 178 : 1533–1545. [CrossRef] [PubMed]
  5. Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. Biochim Biophys Acta 2004 ; 1673 : 75–93. [CrossRef] [PubMed]
  6. Rabinovich GA, Toscano MA. Turning sweet on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009 ; 9 : 338–352. [CrossRef] [PubMed]
  7. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002 ; 1572 : 232–254. [CrossRef] [PubMed]
  8. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry (Mosc) 1998 ; 37 : 4086–4092. [CrossRef]
  9. Morris S, Ahmad N, André S, et al. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology 2004 ; 14 : 293–300. [CrossRef] [PubMed]
  10. Lepur A, Salomonsson E, Nilsson UJ, Leffler H. Ligand induced galectin-3 protein self-association. J Biol Chem 2012 ; 287 : 21751–21756. [CrossRef] [PubMed]
  11. Gauthier L, Rossi B, Schiff C. La galectine-1 est un ligand du récepteur des lymphocytes pré-B. Med Sci (Paris) 2003 ; 19 : 144–146. [CrossRef] [EDP Sciences] [PubMed]
  12. Elantak L, Espeli M, Boned A, et al. Structural basis for galectin-1-dependent pre-B cell receptor (pre-BCR) activation. J Biol Chem 2012 ; 287 : 44703–44713. [CrossRef] [PubMed]
  13. Cummings RD, Liu FT. Galectins. In : Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology (chapter 33). 2nd ed. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press, 2009.
  14. Delacour D, Koch A, Jacob R. The role of galectins in protein trafficking. Traffic 2009 ; 10 : 1405–1413. [CrossRef] [PubMed]
  15. Villeneuve C, Baricault L, Canelle L, et al. Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell 2011 ; 22 : 999–1013. [CrossRef] [PubMed]
  16. Lakshminarayan R, Wunder C, Becken U, et al. Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat Cell Biol 2014 ; 16 : 595–606. [CrossRef] [PubMed]
  17. Gendronneau G, Sidhu SS, Delacour D, et al. Galectin-7 in the control of epidermal homeostasis after injury. Mol Biol Cell 2008 ; 19 : 5541–5549. [CrossRef] [PubMed]
  18. Georgiadis V, Stewart HJS, Pollard HJ, et al. Lack of galectin-1 results in defects in myoblast fusion and muscle regeneration. Dev Dyn 2007 ; 236 : 1014–1024. [CrossRef] [PubMed]
  19. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006 ; 103 : 15975–15980. [CrossRef]
  20. Boscher C, Zheng YZ, Lakshminarayan R, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem 2012 ; 287 : 32940–32952. [CrossRef] [PubMed]
  21. Goetz JG, Joshi B, Lajoie P, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 2008 ; 180 : 1261–1275. [CrossRef] [PubMed]
  22. Hikita C, Vijayakumar S, Takito J, et al. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin-3. J Cell Biol 2000 ; 151 : 1235–1246. [CrossRef] [PubMed]
  23. Gendronneau G, Sanii S, Dang T, et al. Overexpression of galectin-7 in mouse epidermis leads to loss of cell junctions and defective skin repair. PLoS One 2015; 10 : e0119031. [CrossRef] [PubMed]
  24. Haudek KC, Spronk KJ, Voss PG, et al. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 2010 ; 1800 : 181–189. [CrossRef] [PubMed]
  25. Vyakarnam A, Dagher SF, Wang JL, Patterson RJ. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 1997 ; 17 : 4730–4737. [PubMed]
  26. Haudek KC, Patterson RJ, Wang JL. SR proteins and galectins: what’s in a name? Glycobiology 2010 ; 20 : 1199–1207. [CrossRef] [PubMed]
  27. Chen HY, Weng IC, Hong MH, Liu FT. Galectins as bacterial sensors in the host innate response. Curr Opin Microbiol 2014 ; 17 : 75–81. [CrossRef] [PubMed]
  28. Stowell SR, Arthur CM, Dias-Baruffi M, et al. Innate immune lectins kill bacteria expressing blood group antigen. Nat Med 2010 ; 16 : 295–301. [CrossRef] [PubMed]
  29. Nieminen J, St-Pierre C, Bhaumik P, et al. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008 ; 180 : 2466–2473. [CrossRef]
  30. Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013 ; 106 : 541–546. [CrossRef] [PubMed]
  31. Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 2014 ; 33 : 285–294. [CrossRef] [PubMed]
  32. Newlaczyl AU, Yu LG. Galectin-3: a jack-of-all-trades in cancer. Cancer Lett 2011 ; 313 : 123–128. [CrossRef] [PubMed]
  33. Sanchez-Ruderisch H, Fischer C, Detjen KM, et al. Tumor suppressor p16 INK4a: downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 2010 ; 277 : 3552–3563. [CrossRef] [PubMed]
  34. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005 ; 65 : 8350–8358. [CrossRef] [PubMed]
  35. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012 ; 120 : 4635–4644. [CrossRef] [PubMed]
  36. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008 ; 172 : 288–298. [CrossRef] [PubMed]
  37. Klyosov A, Zomer E, Platt D. DAVANAT® (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies. In : Klyosov AA, ed. Glycobiology and drug design, vol. 1102. Washington, DC : American Chemical Society, 2012 : 89–130. [CrossRef]
  38. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014 ; 40 : 307–319. [CrossRef] [PubMed]
  39. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012 ; 185 : 537–546. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.